Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system
{{output}}
What is known and objective: Eltrombopag is an orally bioavailable drug developed as a second-line treatment for immune thrombocytopenia. However, there are limited reports on thrombotic events related to eltrombopag use. This st... ...
